Anticipation is building at Medscape Education as the team prepares for the EHA 2024 Congress. Medscape Education is excited ...

There are now countless incredible examples of how artificial intelligence (AI) is transforming patient care to predict and ...

The European Commission (EC) has finalised new rules for the joint clinical assessment of medicines to contribute to faster ...

Johnson & Johnson (J&J) has announced it has entered into a definitive agreement with Numab Therapeutics to acquire its ...

On the Global Health Beat, Matthew Durham, our Director of Global Media; Juan Pedro Franco, General Director, Fidia ...

Going beyond the sales rep to NPP channels is becoming critical in Europe, as this new PM360 article by our Director of ...

Eli Lilly has announced that it will be investing an additional $5.3bn in its two new US manufacturing sites, bringing the total spend up to $9bn and making it the largest manufacturing investment in ...

GSK has shared positive headline results from two late-stage studies of its “ultra-long-acting” biologic, depemokimab, in patients with severe asthma. The phase 3 SWIFT-1 and SWIFT-2 trials have been ...

In a recent client meeting about improving diversity in their trials, one of the team said – and I paraphrase: ‘I’m worried that if we push too hard for a diverse trial, the commercial team just ...

Merck KGaA has announced it has signed a definitive agreement to acquire Mirus Bio in a deal worth $600m, which will complement its current portfolio of novel modalities. Anticipated to close in the ...

The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies Sanofi and Sobi’s Altuviiio (antihaemophilic factor [recombinant], Fc-VWF-XTEN fusion ...

Gilead Sciences has announced promising results from an open-label extension study of its investigational PPAR delta agonist, seladelpar, in patients with primary biliary cholangitis (PBC). Affecting ...